Alliance Pharma plc (APH) - Total Assets
Based on the latest financial reports, Alliance Pharma plc (APH) holds total assets worth GBX369.14 Million GBX (≈ $44.91K USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore APH operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Alliance Pharma plc - Total Assets Trend (1999–2024)
This chart illustrates how Alliance Pharma plc's total assets have evolved over time, based on quarterly financial data. See Alliance Pharma plc book value and equity for net asset value and shareholders' equity analysis.
Alliance Pharma plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Alliance Pharma plc's total assets of GBX369.14 Million consist of 28.3% current assets and 71.7% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 8.8% |
| Accounts Receivable | GBX46.34 Million | 12.6% |
| Inventory | GBX22.52 Million | 6.1% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX240.86 Million | 65.3% |
| Goodwill | GBX12.74 Million | 3.5% |
Asset Composition Trend (1999–2024)
This chart illustrates how Alliance Pharma plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Alliance Pharma plc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alliance Pharma plc's current assets represent 28.3% of total assets in 2024, a decrease from 67.4% in 1999.
- Cash Position: Cash and equivalents constituted 8.8% of total assets in 2024, down from 31.1% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 68.0% of total assets, an increase from 31.0% in 1999.
- Asset Diversification: The largest asset category is intangible assets at 65.3% of total assets.
Alliance Pharma plc Competitors by Total Assets
Key competitors of Alliance Pharma plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Alkermes plc
F:8AK
|
Germany | €4.26 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
Alliance Pharma plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.84 | 2.57 | 2.69 |
| Quick Ratio | 2.23 | 1.93 | 2.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX67.64 Million | GBX63.52 Million | GBX40.83 Million |
Alliance Pharma plc - Advanced Valuation Insights
This section examines the relationship between Alliance Pharma plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.68 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -11.0% |
| Total Assets | GBX369.14 Million |
| Market Capitalization | $4.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Alliance Pharma plc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Alliance Pharma plc's assets decreased by 11.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Alliance Pharma plc (1999–2024)
The table below shows the annual total assets of Alliance Pharma plc from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX369.14 Million ≈ $44.91K |
-11.03% |
| 2023-12-31 | GBX414.92 Million ≈ $50.48K |
-22.79% |
| 2022-12-31 | GBX537.41 Million ≈ $65.39K |
+6.74% |
| 2021-12-31 | GBX503.49 Million ≈ $61.26K |
-1.05% |
| 2020-12-31 | GBX508.85 Million ≈ $61.91K |
+24.83% |
| 2019-12-31 | GBX407.64 Million ≈ $49.60K |
+1.00% |
| 2018-12-31 | GBX403.61 Million ≈ $49.11K |
+19.95% |
| 2017-12-31 | GBX336.48 Million ≈ $40.94K |
+4.91% |
| 2016-12-31 | GBX320.74 Million ≈ $39.02K |
+9.77% |
| 2015-12-31 | GBX292.19 Million ≈ $35.55K |
+170.88% |
| 2014-12-31 | GBX107.87 Million ≈ $13.12K |
+0.82% |
| 2013-12-31 | GBX106.99 Million ≈ $13.02K |
+6.33% |
| 2012-12-31 | GBX100.63 Million ≈ $12.24K |
+22.29% |
| 2011-12-31 | GBX82.29 Million ≈ $10.01K |
+6.32% |
| 2010-12-31 | GBX77.40 Million ≈ $9.42K |
+36.26% |
| 2009-12-31 | GBX56.80 Million ≈ $6.91K |
+16.32% |
| 2008-12-31 | GBX48.83 Million ≈ $5.94K |
+5.23% |
| 2007-12-31 | GBX46.41 Million ≈ $5.65K |
-3.46% |
| 2006-12-31 | GBX48.07 Million ≈ $5.85K |
+34.41% |
| 2005-12-31 | GBX35.76 Million ≈ $4.35K |
+4.27% |
| 2005-02-28 | GBX34.30 Million ≈ $4.17K |
+29.72% |
| 2004-02-29 | GBX26.44 Million ≈ $3.22K |
+27.02% |
| 2003-02-28 | GBX20.82 Million ≈ $2.53K |
+820.61% |
| 2002-12-31 | GBX2.26 Million ≈ $275.10 |
-74.38% |
| 2002-02-28 | GBX8.82 Million ≈ $1.07K |
+121.32% |
| 2001-02-28 | GBX3.99 Million ≈ $485.10 |
-8.43% |
| 2000-02-29 | GBX4.35 Million ≈ $529.76 |
-33.71% |
| 1999-02-28 | GBX6.57 Million ≈ $799.14 |
-- |
About Alliance Pharma plc
Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated i… Read more